

S1 Table. Patients' demographic and clinical data

Patient ID	Age	Stage ^{a)}	Histological type	HPV type	Microsatellite instability	Neoadjuvant chemotherapy	Pathologic response ^{b)}	Percent of residual viable tumor (%)	Adjuvant chemotherapy
CC_086	47	II A	SQCC	16	MSS	Paclitaxel plus carboplatin, one cycle	Non-MPR	20-30	Paclitaxel plus carboplatin, three cycles
CC_061	43	II A	SQCC	16	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	20	Paclitaxel liposome plus carboplatin, three cycles
CC_106	31	I B	ADC	16	MSS	Paclitaxel plus carboplatin, one cycle	Non-MPR	> 90	Paclitaxel plus carboplatin, three cycles
CC_089	50	II A	SQCC	Group A7	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	30	Paclitaxel liposome plus carboplatin, three cycles
CC_087	48	I B	SQCC	n/a	MSS	Paclitaxel plus carboplatin, one cycle	Non-MPR	90	Paclitaxel plus carboplatin, three cycles
CC_069	41	I B	SQCC	18	MSS	Paclitaxel plus nedaplatin, one cycle	MPR	< 10	Paclitaxel plus nedaplatin, three cycles
CC_081	44	I B	ADC	16	MSI	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	> 80	Paclitaxel liposome plus carboplatin, three cycles
CC_076	42	II A	SQCC	n/a	MSS	Paclitaxel plus cisplatin, one cycle	Non-MPR	50	Paclitaxel plus cisplatin, three cycles
CC_110	55	I B	ADC	n/a	MSS	Paclitaxel plus cisplatin, one cycle	Non-MPR	70-80	Paclitaxel plus cisplatin, three cycles
CC_083	44	II A	SQCC	16	MSS	Paclitaxel plus nedaplatin, one cycle	Non-MPR	10-20	Paclitaxel plus nedaplatin, three cycles
CC_101	56	I B	SQCC	16	MSI	Paclitaxel liposome plus nedaplatin, one cycle	MPR	<10	Paclitaxel liposome plus nedaplatin, three cycles
CC_044	49	II A	SQCC	16	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	60-70	Paclitaxel liposome plus nedaplatin, three cycles
CC_102	41	I B	SQCC	16	MSS	Paclitaxel liposome plus cisplatin, one cycle	Non-MPR	50	Paclitaxel liposome plus cisplatin, three cycles
CC_107	29	II A	ADC	16	MSS	Paclitaxel plus carboplatin, one cycle	Non-MPR	50	Paclitaxel plus carboplatin, three cycles
CC_111	42	I B	SQCC	16	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	50-60	Paclitaxel liposome plus carboplatin, three cycles
CC_104	35	I B	SQCC	33	MSS	Paclitaxel liposome plus cisplatin, one cycle	Non-MPR	>90	Paclitaxel liposome plus cisplatin, three cycles

CC_067	45	I B	SQCC	18	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	50-60	Paclitaxel liposome plus nedaplatin, three cycles
CC_084	48	I B	SQCC	n/a	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	80	Paclitaxel liposome plus carboplatin, three cycles
CC_096	53	I B	SQCC	52	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	>90	Paclitaxel liposome plus carboplatin, three cycles
CC_066	43	I B	SQCC	16	MSS	Paclitaxel plus carboplatin, one cycle	Non-MPR	80	Paclitaxel plus carboplatin, three cycles
CC_100	47	I B	SQCC	16	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	90	Paclitaxel liposome plus carboplatin, three cycles
CC_048	33	I B	SQCC	n/a	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	10-20	Paclitaxel liposome plus nedaplatin, three cycles
CC_060	46	II A	SQCC	16	MSS	Paclitaxel plus nedaplatin, one cycle	pCR	0	Paclitaxel plus nedaplatin, three cycles
CC_093	27	II A	SQCC	58	MSS	Paclitaxel liposome plus carboplatin, one cycle	MPR	<10	Paclitaxel liposome plus carboplatin, three cycles
CC_047	53	I B	SQCC	16	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	>90	Paclitaxel liposome plus carboplatin, three cycles
CC_059	46	II A	SQCC	n/a	MSS	Paclitaxel plus nedaplatin, one cycle	Non-MPR	40-50	Paclitaxel plus nedaplatin, three cycles
CC_072	38	I B	ADC	31	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	20-30	Paclitaxel liposome plus nedaplatin, three cycles
CC_112	28	I B	SQCC	n/a	MSS	Paclitaxel plus carboplatin, one cycle	Non-MPR	40-50	Paclitaxel plus carboplatin, three cycles
CC_070	41	II A	SQCC	16	MSS	Paclitaxel liposome plus cisplatin, one cycle	Non-MPR	70-80	Paclitaxel liposome plus cisplatin, three cycles
CC_045	36	I B	SQCC	n/a	MSS	Albumin bound paclitaxel plus carboplatin, one cycle	Non-MPR	80	Albumin bound paclitaxel plus carboplatin, three cycles
CC_071	26	I B	SQCC	16	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	50	Paclitaxel liposome plus nedaplatin, three cycles
CC_094	58	II A	SQCC	n/a	MSS	Paclitaxel liposome plus cisplatin, one cycle	MPR	<10	Paclitaxel liposome plus cisplatin, three cycles

CC_079	41	II A	SQCC	n/a	MSS	Paclitaxel liposome plus lobaplatin, one cycle	Non-MPR	40-50	Paclitaxel liposome plus lobaplatin, three cycles
CC_010	49	I B	SQCC	16	MSS	Paclitaxel plus carboplatin, one cycle	MPR	<10	Paclitaxel plus carboplatin, three cycles
CC_077	57	II A	SQCC	n/a	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	50-60	Paclitaxel liposome plus carboplatin, three cycles
CC_085	55	II A	ADC	18	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	10-20	Paclitaxel liposome plus nedaplatin, three cycles
CC_064	48	I B	ADC	16	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	>90	Paclitaxel liposome plus carboplatin, three cycles
CC_024	56	I B	ADC	n/a	MSS	Docetaxel plus nedaplatin, one cycle	MPR	<10	Docetaxel plus nedaplatin, three cycles
CC_055	54	II A	SQCC	16	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	20	Paclitaxel liposome plus carboplatin, three cycles
CC_015	41	I B	SQCC	n/a	MSS	Paclitaxel liposome plus nedaplatin, one cycle	pCR	0	Paclitaxel liposome plus nedaplatin, three cycles
CC_020	54	II A	ASC	16	MSI	Paclitaxel plus carboplatin, one cycle	Non-MPR	20	Paclitaxel plus carboplatin, three cycles
CC_013	56	II A	SQCC	16	MSS	Paclitaxel liposome plus nedaplatin, one cycle	MPR	<10	Paclitaxel liposome plus nedaplatin, three cycles
CC_012	58	II A	SQCC	18	MSS	Paclitaxel plus carboplatin, one cycle	Non-MPR	20-30	Paclitaxel plus carboplatin, three cycles
CC_007	44	II A	SQCC	16	MSS	Paclitaxel plus nedaplatin, one cycle	Non-MPR	30-40	Paclitaxel plus nedaplatin, three cycles
CC_028	60	I B	SQCC	58	MSS	Paclitaxel liposome plus carboplatin, one cycle	MPR	<10	Paclitaxel liposome plus carboplatin, three cycles
CC_034	66	I B	SQCC	16	MSS	Paclitaxel liposome plus carboplatin, one cycle	MPR	<10	Paclitaxel liposome plus carboplatin, three cycles
CC_022	48	II A	SQCC	n/a	MSS	Docetaxel plus cisplatin, one cycle	Non-MPR	70-80	Docetaxel plus cisplatin, three cycles
CC_014	47	I B	SQCC	16	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	<50	Paclitaxel liposome plus carboplatin, three cycles
CC_030	37	I B	SQCC	18	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	>50	Paclitaxel liposome plus carboplatin, three cycles

CC_018	55	II A	SQCC	n/a	MSS	Paclitaxel liposome plus cisplatin, one cycle	Non-MPR	>90	Paclitaxel liposome plus cisplatin, three cycles
CC_054	53	I B	SQCC	16	MSS	Docetaxel plus nedaplatin, one cycle	MPR	<10	Docetaxel plus nedaplatin, three cycles
CC_027	44	I B	SQCC	n/a	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	20-30	Paclitaxel liposome plus nedaplatin, three cycles
CC_056	43	II A	SQCC	16	MSS	Docetaxel plus nedaplatin, one cycle	Non-MPR	90	Docetaxel plus nedaplatin, three cycles
CC_019	36	I B	SQCC	n/a	MSS	Paclitaxel liposome plus carboplatin, one cycle	Non-MPR	30-40	Paclitaxel liposome plus carboplatin, three cycles
CC_025	41	II A	ASC	16	MSS	Paclitaxel plus carboplatin, one cycle	MPR	<10	Paclitaxel plus carboplatin, three cycles
CC_006	35	II A	ADC	52	MSS	Paclitaxel plus carboplatin, one cycle	Non-MPR	40-50	Paclitaxel plus carboplatin, three cycles
CC_037	51	I B	SQCC	45	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	50-60	Paclitaxel liposome plus nedaplatin, three cycles
CC_008	50	II A	SQCC	n/a	MSS	docetaxel plus cisplatin, one cycle	Non-MPR	50-60	docetaxel plus cisplatin, three cycles
CC_023	51	I B	SQCC	16	MSS	docetaxel plus nedaplatin, one cycle	Non-MPR	70-80	docetaxel plus nedaplatin, three cycles
CC_033	52	II A	SQCC	16	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	70-80	Paclitaxel liposome plus nedaplatin, three cycles
CC_036	59	II A	SQCC	18	MSS	Docetaxel plus nedaplatin, one cycle	Non-MPR	70-80	Docetaxel plus nedaplatin, three cycles
CC_039	50	I B	SQCC	16	MSS	Paclitaxel liposome plus nedaplatin, one cycle	Non-MPR	70-80	Paclitaxel liposome plus nedaplatin, three cycles

ADC, adenocarcinoma; ASC, adenosquamous carcinoma; MSI, microsatellite unstable; MSS, microsatellite stable; n/a, not available; SQCC, squamous carcinoma. ^{a)}The International Federation of Gynecology and Obstetrics (International Federation of Gynecology and Obstetrics) 2009, ^{b)}MPR, major pathologic response; pCR, complete pathologic response. The definition of MPR was initially described by Hellmann et al. (2014) [1].

Reference

1. Hellmann MD, Chaft JE, William WN, Jr., Rusch V, Pisters KM, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. *Lancet Oncol.* 2014;15:e42-50.